News
Survival of patients with mCRPC on hormone therapy differs by race
- Author:
- Susan London
SAN FRANCISCO – An analysis of male veterans finds that African American men with chemotherapy-naive mCRPC treated with abiraterone or...
News
Pembrolizumab-axitinib nearly halves risk of death in RCC
- Author:
- Susan London
SAN FRANCISCO – Pembrolizumab and axitinib combination therapy netted superior progression-free and overall survival relative to sunitinib in...
News
Radioligand is highly active in metastatic castrate-resistant prostate cancer
- Author:
- Susan London
SAN FRANCISCO – Lutetium-177 PSMA-617 (LuPSMA) netted a high rate of PSA response and impressive overall survival among patients who had run out...
News

Pancreatic cancer expression signature is linked to chemoresistance
- Author:
- Susan London
SAN FRANCISCO – Whole-genome and RNA sequencing of pancreatic cancers in the COMPASS trial has tied an RNA expression signature to poorer survival...
News

Gastrectomy does not alter benefit of new oral chemo in gastric cancer
- Author:
- Susan London
SAN FRANCISCO – In the phase 3 TAGS trial, the gastrectomy subgroup did have higher rates of grade 3 or 4 adverse events.
News

Cancer vaccine fails in CRC but trial yields lessons
- Author:
- Susan London
SAN FRANCISCO – Tecemotide did not improve recurrence-free or overall survival relative to placebo when given after R0/R1 resection of liver-only...
News

Dual BRAF, MEK inhibition proves highly active in biliary tract cancer
- Author:
- Susan London
SAN FRANCISCO – Patients with BRAF V600E–mutated biliary tract cancer in a basket trial had a response rate of 42% when given the combination of...
News

mRECIST response to kinase inhibitors predicts survival in HCC
- Author:
- Susan London
SAN FRANCISCO – Among patients with untreated HCC given first-line kinase inhibitors, those having a response based on mRECIST criteria lived...
News

Pembrolizumab bests chemo in PD-L1-positive esophageal cancer
- Author:
- Susan London
SAN FRANCISCO – In KEYNOTE-181, second-line pembrolizumab reduced risk of death by 31% relative to chemotherapy among patients whose esophageal...
News

Age may dictate benefit of andecaliximab in gastric cancer
- Author:
- Susan London
SAN FRANCISCO – Older adults appeared to derive both progression-free and overall survival benefit in the GAMMA-1 trial, which tested addition of...
News

COLOPEC: Adjuvant HIPEC for high-risk colon cancer disappoints
- Author:
- Susan London
SAN FRANCISCO – Adding adjuvant oxaliplatin HIPEC to routine adjuvant systemic chemotherapy did not improve survival without peritoneal recurrence...
News

Young women opt for mastectomy even when neoadjuvant chemo works well
- Author:
- Susan London
SAN ANTONIO – Although neoadjuvant chemotherapy doubled the proportion of women eligible for breast-conserving surgery, about 40% chose mastectomy...
News
Older breast cancer patients given adjuvant chemo live longer
- Author:
- Susan London
SAN ANTONIO – Overall survival is better in breast cancer patients aged 65 years and older who receive adjuvant chemotherapy, although patients...
News

QOL is poorer for young women after mastectomy than BCS
- Author:
- Susan London
SAN ANTONIO – A cohort study of 560 breast cancer survivors aged 40 or younger at diagnosis finds that breast satisfaction and several domains of...
News

Oxybutynin rapidly quells hot flashes
- Author:
- Susan London
SAN ANTONIO - Oxybutynin reduced hot flash scores by at least two-thirds, improved measures of quality of life, and was safe and well tolerated in...